MAP.3 Trial: Breast Cancer Prevention with Exemestane
Author Information
Author(s): Richardson H., Johnston D., Pater J., Goss P.
Primary Institution: National Cancer Institute of Canada Clinical Trials Group
Hypothesis
A greater reduction in breast cancer incidence with fewer side effects is hypothesized with aromatase inhibitors than with tamoxifen or raloxifene.
Conclusion
The MAP.3 trial aims to determine the efficacy of exemestane in reducing breast cancer incidence in postmenopausal women at increased risk.
Supporting Evidence
- Exemestane is capable of inhibiting aromatase action by more than 95%.
- The incidence of contralateral primary breast cancer was significantly lower in the anastrozole group than in the tamoxifen group.
- Tamoxifen and raloxifene can reduce the incidence of invasive breast cancer by up to 50%.
- The study aims to compare the incidence of breast cancer in the two treatment groups.
Takeaway
This study is testing a medicine called exemestane to see if it can help prevent breast cancer in women who are more likely to get it.
Methodology
The study is a randomized double-blind placebo-controlled trial comparing exemestane to placebo in postmenopausal women at increased risk for breast cancer.
Potential Biases
Potential bias in participant selection and adherence to treatment protocols.
Limitations
The study was halted and revised due to safety concerns related to cardiovascular risks associated with other medications.
Participant Demographics
Postmenopausal women aged 35 and older at increased risk for breast cancer.
Statistical Information
P-Value
0.013
Confidence Interval
95% CI: 0.66 to 0.88
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website